Nitroglycerin Patches Do Not Improve Stroke Outcomes
By HospiMedica International staff writers Posted on 20 Feb 2019 |
Image: A new study claims that nitroglycerin patches are ineffectual for lowering blood pressure during stroke (Photo courtesy of Medscape).
Transdermal delivery of nitroglycerin to lower blood pressure in suspected stroke patients does not lessen post-stroke disability, according to a new study.
Researchers at the University of Nottingham (Nottingham; United Kingdom) conducted a multicenter prospective randomized trial to investigate whether it is safe and effective for paramedics to administer nitroglycerin. The study included 1,149 patients (average age 73, 52% male) with presumed stroke and systolic blood pressure above 120 mm Hg, who were randomized to receive either a nitroglycerin patch or a sham patch in the ambulance within four hours of symptom onset. The primary outcome was a shift in disability measured at three months.
The results revealed that at 90 days, there was no difference among the overall trial population, with an average of 3 points on the 7-point scale modified Rankin Scale (mRS) in both those who got the patch and those who got sham dressings, even among those with a final diagnosis of stroke or transient ischemic stroke. Secondary outcomes revealed that the intervention was worse in patients with intracerebral hemorrhage, and those enrolled within an hour of symptom onset. The study was presented at the annual International Stroke Conference, held during January 2019 in Honolulu (HW, USA).
“More than half had been diagnosed with high blood pressure, 24% had a previous stroke, while 20% had diabetes or atrial fibrillation; the primary outcome was a shift in disability measured at three months. However, nitroglycerin did not improve overall outcome,” said lead author Professor Philip Bath, DSc, of the University of Nottingham. “In patients with a brain bleed, the patch appeared to worsen outcomes. So, treatment with nitroglycerin cannot be recommended very early after stroke.”
Nitroglycerin (1,2,3-trinitroxypropane), is a dense, colorless, oily, explosive liquid which for over 130 years has been used as a potent vasodilator to treat various heart conditions, such as angina pectoris and chronic heart failure (CHF). The beneficial effects are due to nitroglycerin being converted to nitric oxide (NO), a potent venous dilator. Nitroglycerin is available in sublingual tablets, sprays, and patches.
Related Links:
University of Nottingham
Researchers at the University of Nottingham (Nottingham; United Kingdom) conducted a multicenter prospective randomized trial to investigate whether it is safe and effective for paramedics to administer nitroglycerin. The study included 1,149 patients (average age 73, 52% male) with presumed stroke and systolic blood pressure above 120 mm Hg, who were randomized to receive either a nitroglycerin patch or a sham patch in the ambulance within four hours of symptom onset. The primary outcome was a shift in disability measured at three months.
The results revealed that at 90 days, there was no difference among the overall trial population, with an average of 3 points on the 7-point scale modified Rankin Scale (mRS) in both those who got the patch and those who got sham dressings, even among those with a final diagnosis of stroke or transient ischemic stroke. Secondary outcomes revealed that the intervention was worse in patients with intracerebral hemorrhage, and those enrolled within an hour of symptom onset. The study was presented at the annual International Stroke Conference, held during January 2019 in Honolulu (HW, USA).
“More than half had been diagnosed with high blood pressure, 24% had a previous stroke, while 20% had diabetes or atrial fibrillation; the primary outcome was a shift in disability measured at three months. However, nitroglycerin did not improve overall outcome,” said lead author Professor Philip Bath, DSc, of the University of Nottingham. “In patients with a brain bleed, the patch appeared to worsen outcomes. So, treatment with nitroglycerin cannot be recommended very early after stroke.”
Nitroglycerin (1,2,3-trinitroxypropane), is a dense, colorless, oily, explosive liquid which for over 130 years has been used as a potent vasodilator to treat various heart conditions, such as angina pectoris and chronic heart failure (CHF). The beneficial effects are due to nitroglycerin being converted to nitric oxide (NO), a potent venous dilator. Nitroglycerin is available in sublingual tablets, sprays, and patches.
Related Links:
University of Nottingham
Latest Critical Care News
- On-Skin Wearable Bioelectronic Device Paves Way for Intelligent Implants
- First-Of-Its-Kind Dissolvable Stent to Improve Outcomes for Patients with Severe PAD
- AI Brain-Age Estimation Technology Uses EEG Scans to Screen for Degenerative Diseases
- Wheeze-Counting Wearable Device Monitors Patient's Breathing In Real Time
- Wearable Multiplex Biosensors Could Revolutionize COPD Management
- New Low-Energy Defibrillation Method Controls Cardiac Arrhythmias
- New Machine Learning Models Help Predict Heart Disease Risk in Women
- Deep-Learning Model Predicts Arrhythmia 30 Minutes before Onset
- Breakthrough Technology Combines Detection and Treatment of Nerve-Related Disorders in Single Procedure
- Plasma Irradiation Promotes Faster Bone Healing
- New Device Treats Acute Kidney Injury from Sepsis
- Study Confirms Safety of DCB-Only Strategy for Treating De Novo Left Main Coronary Artery Disease
- Revascularization Improves Quality of Life for Patients with Chronic Limb Threatening Ischemia
- AI-Driven Prediction Models Accurately Predict Critical Care Patient Deterioration
- Preventive PCI for High-Risk Coronary Plaques Reduces Cardiac Events
- AI Diagnostic Tool Guides Rapid Diagnosis and Prediction of Sepsis